CoChat

Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process

Hoshi, Kanako, Takakura, Hideki, Mitani, Yasumasa, Tatsumi, Kenji, Momiyama, Nobuyoshi, Ichikawa, Yasushi, Togo, Shinji, Miyagi, Toru, Kawai, Yuki, Kogo, Yasushi, Kikuchi, Takeshi, Kato, Chiaki, Arakawa, Takahiro, Uno, Syuji, Cizdziel, Paul E., Lezhava, Alexander, Ogawa, Noburou, Hayashizaki, Yoshihide, Shimada, Hiroshi · 2007 · Clinical Cancer Research
Cited by 90

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Purpose: A positive response to gefitinib in non–small cell lung cancer (NSCLC) has been correlated to mutations in epidermal growth factor receptor (EGFR) gene. Previous reports have been based mainly on diagnostic screening by sequencing. However, sequencing is a time-consuming and complicated procedure, not suitable for routine clinical use. Experimental Design: We have developed rapid, simple, and sensitive mutation detection assays based on the SMart Amplification Process (SMAP) and applied it for analyzing EGFR gene mutations in clinical samples. By using SMAP, we can detect mutations within 30 min including sample preparation. To validate the assay system for potential use in clinical diagnostics, we examined 45 NSCLC patients for EGFR mutations using sequencing and SMAP. Results: The outcomes of the SMAP assay perfectly matched the sequencing results, except in one case where SMAP was able to identify a mutation that was not detected by sequencing. We also evaluated the sensitivity and specificity of SMAP in mutation detection for EGFR. In a serial dilution study, SMAP was able to find a mutation in a sample containing only 0.1% of the mutant allele in a mixture of wild-type genomic DNA. We also could show amplification of mutated DNA with only 30 copies per reaction. Conclusions: The SMAP method offers higher sensitivity and specificity than alternative technologies, while eliminating the need for sequencing to identify mutations in the EGFR gene of NSCLC. It provides a robust and point-of-care accessible approach for a rapid identification of most patients likely to respond to gefitinib.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-07-0509

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 90

Metadata

Authors
Hoshi, K., Takakura, H., Mitani, Y., Tatsumi, K., Momiyama, N., Ichikawa, Y., Togo, S., Miyagi, T., Kawai, Y., Kogo, Y., Kikuchi, T., Kato, C., Arakawa, T., Uno, S., Cizdziel, P. E., Lezhava, A., Ogawa, N., Hayashizaki, Y., & Shimada, H.
Venue
Clinical Cancer Research
Published
2007-09-01
Volume
13
Issue
17
Pages
4974-4983
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2109361793
Cited by
90
References
1
FWCI
5.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0509
The paper
Hoshi, K., Takakura, H., Mitani, Y., Tatsumi, K., Momiyama, N., Ichikawa, Y., Togo, S., Miyagi, T., Kawai, Y., Kogo, Y., Kikuchi, T., Kato, C., Arakawa, T., Uno, S., Cizdziel, P. E., Lezhava, A., Ogawa, N., Hayashizaki, Y., & Shimada, H. (2007). Rapid Detection of Epidermal Growth Factor Receptor Mutations in Lung Cancer by the SMart-Amplification Process. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0509

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.